Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	22.95	45.01	19.52	47.62	71.54
Short-Term Investments	147.36	0	321.59	363.57	998.32
Cash & Cash Equivalents	170.31	45.01	341.11	411.19	1,070
Cash Growth	278.41%	-86.81%	-17.04%	-61.57%	34.34%
Receivables	32.92	30.42	85.45	56.85	30.39
Inventory	23.97	13.29	27.33	26.49	7.3
Other Current Assets	10.23	174.88	10.86	6.04	16.1
Total Current Assets	237.43	263.6	464.75	500.56	1,124
Property, Plant & Equipment	25.06	27.49	32.6	37.17	17.62
Long-Term Investments	49.32	3	0	0	0
Goodwill and Intangibles	402.98	458.31	492.47	795.97	325.77
Other Long-Term Assets	72.43	10.27	307.76	28.59	27.88
Total Long-Term Assets	549.79	499.07	832.84	861.73	371.27
Total Assets	787.22	762.67	1,298	1,362	1,495
Accounts Payable	2.43	5.31	8.4	3.78	2.42
Deferred Revenue	2.67	0.4	0.65	29.44	2.14
Current Debt	0.41	77.41	1.41	8.48	1.26
Other Current Liabilities	11.28	15.69	31.2	58.41	11.19
Total Current Liabilities	16.78	98.81	41.67	100.11	17
Long-Term Debt	5.76	10.34	322.97	447.94	648.93
Other Long-Term Liabilities	63.77	56.04	111.79	104.71	61.75
Total Long-Term Liabilities	69.52	66.37	434.77	552.65	710.68
Total Liabilities	86.3	165.18	476.43	652.76	727.68
Total Debt	6.17	87.75	324.39	456.41	650.18
Debt Growth	-92.97%	-72.95%	-28.93%	-29.80%	2.18%
Retained Earnings	503.02	450.86	449.09	391.95	400.11
Comprehensive Income	-0.82	-0.98	-0.92	-0.8	-0.22
Shareholders' Equity	700.91	597.49	821.16	709.53	767.23
Net Cash / Debt	164.14	-42.74	16.72	-45.23	419.68
Net Cash / Debt Growth	-	-	-	-	162.12%
Net Cash Per Share	9.24	-2.53	0.97	-2.69	21.24
Working Capital	220.65	164.79	423.09	400.45	1,107
Book Value Per Share	40.52	35.42	49.38	43.84	40.39

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).